X-Nav Technologies Reports X-Guide Dynamic Navigation Receives FDA 510(k) Clearance To Aid in Minimally Invasive Endodontic Procedures

X-Nav Technologies, LLC, a leading creator of image-guided and robot-assisted surgical products, announced that it has received clearance from the U.S. Food and Drug Administration to expand the use of its X-Guide® Dynamic Surgical Navigation system to aid dentists in delivering minimally invasive endodontic procedures.

According to X-Nav Technologies, with the X-Guide dynamic navigation, patients and dentists can now benefit from more precise and minimally invasive access to tooth structures needing endodontic treatment – specifically, access to calcified canals and apicoectomies of affected teeth.

“X-Guide dynamic navigation is an extremely accurate solution to a common endodontic challenge: calcified root canal systems,” according to L. Stephen Buchanan, DDS, FICD, FACD of Santa Barbara, CA. “With X-Guide, I can perform minimally invasive root canal therapy (RCT) with much more predictability and less stress.”

Using the X-Guide system’s patented X-Point™ technology, the dentist gains a live view of the patient’s 3D anatomy and a digital handpiece to guide drill movements during surgery. This allows the dentist to precisely navigate their drill to an exact access location for more efficient endodontic procedures. Tools in the X-Guide software help make navigation easy to integrate into the endodontic workflow, like the virtual Prep feature for planning and following an ideal drill path, X-Mark™ virtual registration for using small, medium and large field of view CBCTs, and integration with high-speed handpieces.

Combining 3D imaging with X-Guide navigation allows dentists to locate and access endodontic tooth structures more precisely, which is useful to:

  • achieve less invasive access and prep of calcified and hidden canals
  • perform minimally invasive apicoectomy and root-end access
  • minimize damage to anatomical structures
  • preserve tooth structure
  • save time and potentially reduce intra-operative imaging

“In teeth with calcification, X-Guide dynamic guidance can be used to reduce structural weakening through minimally-invasive endodontic procedures,” stated Dr. Charles Maupin, DDS of Lubbock, TX.

According to studies, “The dynamic navigation system was more accurate and more efficient in root-end resection in a cadaver model than the freehand technique. The dynamic navigation system has the potential to be a safe and reliable technological addition to endodontic microsurgery.”1

Dr. Frederico Martinho, DDS, M.Sc., PhD, and Clinical Associate Professor at the University of Maryland School of Dentistry, shared that “Our recent studies with X-Guide focused on minimally invasive access cavity, post removal, locating calcified canals, and endodontic microsurgery. It has the potential to improve accuracy, reduce surgical time, and operator mishaps. Both the endodontic residents and I were able to quickly master the technology – the learning curve was not steep for novel or experienced endodontists.”

X-Nav Technologies notes the X-Guide system has gained global recognition for giving dental surgeons the ability to perform more accurate and precise dental implant procedures, compared to freehand surgery. Over 175,000 dental implants have been surgically placed using the X-Guide system around the world.

“As X-Guide surgical navigation became an integral part of dental implant surgery, it also became clear that expanding access to our technology for endodontic procedures would improve provider capabilities and patient experiences. I’m proud of our talented team of clinical and engineering masterminds for being able to deliver the benefits of surgical navigation to more dental professionals,” said Edward Marandola, President, CEO, and Co-Founder of X-Nav Technologies.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version